Conditions · Pancreatic cancer
Pancreatic cancer — drug options
30 open options
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
RP-001
- TRIALNARECRUITING
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
BGT007H Cell Injection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
VB15010 — 1 site
- TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC) — 1 site
- TRIALEARLY_PHASE1RECRUITING
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
ES502 Injection — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Nogapendekin Alfa Inbakicept (N803) · Sotevtamab · Zabadinostat (CXD101)
- TRIALPHASE2RECRUITING
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Folfirinox — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
- TRIALNANOT_YET_RECRUITING
Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer
Thermal Ablation · Chemotherapy
- TRIALPHASE3RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Ferric carboxymaltose · Placebo — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Vitmain C plus herbal medicine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Carbon Nanoparticle-Loaded Iron [CNSI-Fe] · Carbon Nanoparticle-Loaded Iron — 9 sites
- TRIALPHASE2RECRUITING
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Low-dose Radiotherapy · Pucotenlimab · AG regimen — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
HLX43 DOSE 1 (2.5 mg/kg) · HLX43 DOSE 2 (3.0 mg/kg)
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALNARECRUITING
Target-specific immunoPET Imaging of Digestive System Carcinoma
[68Ga]Ga-DOTA-H2D3 · [18F]F-RESCA-RB14 · [68Ga]Ga-NOTA-T4 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
Adebrelimab · mRNA tumor vaccines — 1 site
- TRIALNARECRUITING
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Later-line therapy — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
HSK41959 · Sintilimab · Pemetrexed + Cisplatin /Carboplatin — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection · Computed Tomography · Electronic Health Record Review — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
JAB-23E73 tablet，nab-paclitaxel，gemcitabine — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) · EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) · Lymphodepleting chemotherapy (Flu/Cy) — 1 site
- TRIALEARLY_PHASE1RECRUITING
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
177Lu-CTR-FAPI — 1 site
- TRIALPHASE2RECRUITING
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Adebrelimab · Oxaliplatin 100 MG · Irinotecan liposome — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Trastuzumab · Pertuzumab — 27 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.